Skip to main content
Erschienen in: Pathology & Oncology Research 2/2018

27.05.2017 | Original Article

MiR-1271 Inhibits Cell Growth in Prostate Cancer by Targeting ERG

verfasst von: Miao Wang, Wei Gao, Dehong Lu, Lianghong Teng

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

ETS-related gene (ERG) is an oncogene that is commonly found in prostate cancer (PCa). Several miRNAs have been reported to be associated with PCa. This study was undertaken to identify miRNAs that act as a tumor suppressor by targeting ERG. We collected 70 PCa and paired adjacent non-tumor (Adjacent-N) tissues and analyzed ERG expression by immunohistochemistry(IHC). Expression of 6 miRNAs (miR-21,-34a,-96,-125b,-150 and miR-1271) was analyzed by qRT-PCR. Luciferase reporter assay was performed to examine miRNA binding to the 3′-UTR of target genes. The effects of ectopic expression of miRNA on cell growth and MAPK signaling pathway were investigated in in PC-3 and LNCaP cell lines. Among 70 PCa cases, 13 (18.6%) were ERG positive. No significant difference of miR-34a, 96, 125b, and 150 expression was found between PCa and Adjacent-N tissues. Significantly higher level of miR-21 and lower level of miR-1271 expression were found in cancer tissues. Furthermore, miR-1271 was down-regulated in ERG-positive PCa cases (p < 0.05). Based on luciferase reporter assay, we identified ERG gene as a direct target gene for miR-1271. Transfection of a miR-1271 mimics into PC-3 and LNCaP cells repressed the ERG expression and significantly suppressed cell growth. Lastly, ectopic expression of miR-1271 inhibits AKT1, p38gama and CREB kinase activity. Our results suggested that reduced expression of miR-1271 may be involved in the ERG expression and that miR-1271 could be a therapeutic target for ERG-positive prostate cancer patients.
Literatur
1.
Zurück zum Zitat Tomlins SA et al (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748):644–648CrossRefPubMed Tomlins SA et al (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748):644–648CrossRefPubMed
2.
Zurück zum Zitat Mosquera JM et al (2009) Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 15(14):4706–4711CrossRefPubMedPubMedCentral Mosquera JM et al (2009) Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 15(14):4706–4711CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Magi-Galluzzi C et al (2011) TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 71(5):489–497CrossRefPubMed Magi-Galluzzi C et al (2011) TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 71(5):489–497CrossRefPubMed
4.
5.
Zurück zum Zitat Shi XB et al (2011) miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate 71(5):538–549CrossRefPubMed Shi XB et al (2011) miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate 71(5):538–549CrossRefPubMed
6.
Zurück zum Zitat Yu JJ et al (2014) miR-96 promotes cell proliferation and clonogenicity by down-regulating of FOXO1 in prostate cancer cells. Med Oncol 31(4):910CrossRefPubMed Yu JJ et al (2014) miR-96 promotes cell proliferation and clonogenicity by down-regulating of FOXO1 in prostate cancer cells. Med Oncol 31(4):910CrossRefPubMed
7.
Zurück zum Zitat Zhang HL et al (2011) Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 71(3):326–331CrossRefPubMed Zhang HL et al (2011) Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 71(3):326–331CrossRefPubMed
8.
Zurück zum Zitat Kojima K et al (2010) MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 70(14):1501–1512CrossRefPubMed Kojima K et al (2010) MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 70(14):1501–1512CrossRefPubMed
10.
Zurück zum Zitat Jensen KP, Covault J (2011) Human miR-1271 is a miR-96 paralog with distinct non-conserved brain expression pattern. Nucleic Acids re 39(2):701–711CrossRef Jensen KP, Covault J (2011) Human miR-1271 is a miR-96 paralog with distinct non-conserved brain expression pattern. Nucleic Acids re 39(2):701–711CrossRef
11.
Zurück zum Zitat Humphrey PA et al (2016) WHO classification: Tumours of the urinary system and male genital organs. IARC Press 94(4):49–64 Humphrey PA et al (2016) WHO classification: Tumours of the urinary system and male genital organs. IARC Press 94(4):49–64
12.
Zurück zum Zitat Wang M et al (2008) miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression. J Pathol 215(1):13–20CrossRefPubMed Wang M et al (2008) miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression. J Pathol 215(1):13–20CrossRefPubMed
13.
Zurück zum Zitat Wang M et al (2009) JNK is constitutively active in mantle cell lymphoma: cell cycle deregulation and polyploidy by JNK inhibitor SP600125. J Pathol 218(1):95–103CrossRefPubMed Wang M et al (2009) JNK is constitutively active in mantle cell lymphoma: cell cycle deregulation and polyploidy by JNK inhibitor SP600125. J Pathol 218(1):95–103CrossRefPubMed
14.
Zurück zum Zitat Suarez CD, Deng X, Hu CD (2014) Targeting CREB inhibits radiation-induced neuroendocrine differentiation and increases radiation-induced cell death in prostate cancer cells. Am J Cancer Res 4(6):850–861PubMedPubMedCentral Suarez CD, Deng X, Hu CD (2014) Targeting CREB inhibits radiation-induced neuroendocrine differentiation and increases radiation-induced cell death in prostate cancer cells. Am J Cancer Res 4(6):850–861PubMedPubMedCentral
15.
Zurück zum Zitat Edlind MP, Hsieh AC (2014) PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl 16(3):378–386CrossRefPubMedPubMedCentral Edlind MP, Hsieh AC (2014) PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl 16(3):378–386CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Chen L et al (2004) ERK1/2 and p38 pathways are required for P2Y receptor-mediated prostate cancer invasion. Cancer Lett 215(2):239–247CrossRefPubMed Chen L et al (2004) ERK1/2 and p38 pathways are required for P2Y receptor-mediated prostate cancer invasion. Cancer Lett 215(2):239–247CrossRefPubMed
17.
Zurück zum Zitat Powell IJ et al (2014) Considering race and the potential for ERG expression as a biomarker for prostate cancer. Perinat Med 11(4):409–412 Powell IJ et al (2014) Considering race and the potential for ERG expression as a biomarker for prostate cancer. Perinat Med 11(4):409–412
18.
Zurück zum Zitat Fayyaz S, Farooqi AA (2013) miRNA and TMPRSS2-ERG do not mind their own business in prostate cancer cells. Immunogenetics 65(5):315–332CrossRefPubMed Fayyaz S, Farooqi AA (2013) miRNA and TMPRSS2-ERG do not mind their own business in prostate cancer cells. Immunogenetics 65(5):315–332CrossRefPubMed
20.
Zurück zum Zitat Suh JH et al (2012) ERG immunohistochemistry and clinicopathologic characteristics in Korean prostate adenocarcinoma patients. Korean J Pathol 46(5):423–428CrossRefPubMedPubMedCentral Suh JH et al (2012) ERG immunohistochemistry and clinicopathologic characteristics in Korean prostate adenocarcinoma patients. Korean J Pathol 46(5):423–428CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Li X et al (2014) MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor PDCD4 and promotes cell transformation, proliferation, and metastasis in renal cell carcinoma. Cell Physiol Biochem 33(6):1631–1642CrossRefPubMed Li X et al (2014) MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor PDCD4 and promotes cell transformation, proliferation, and metastasis in renal cell carcinoma. Cell Physiol Biochem 33(6):1631–1642CrossRefPubMed
22.
Zurück zum Zitat Zhang JG et al (2010) MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta 411(11–12):846–852CrossRefPubMed Zhang JG et al (2010) MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta 411(11–12):846–852CrossRefPubMed
23.
Zurück zum Zitat Guan Y et al (2016) Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy. Prostate 76(11):986–993CrossRefPubMed Guan Y et al (2016) Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy. Prostate 76(11):986–993CrossRefPubMed
25.
Zurück zum Zitat Ma Y et al (2012) miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut 61(10):1447–1453CrossRefPubMed Ma Y et al (2012) miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut 61(10):1447–1453CrossRefPubMed
26.
Zurück zum Zitat Liu DZ et al (2015) MIR-150 promotes prostate cancer stem cell development via suppressing p27Kip1. Eur rev med Pharmacol Sci 19(22):4344–4352PubMed Liu DZ et al (2015) MIR-150 promotes prostate cancer stem cell development via suppressing p27Kip1. Eur rev med Pharmacol Sci 19(22):4344–4352PubMed
27.
Zurück zum Zitat Zhong J et al (2017) Inhibition of DIXDC1 by microRNA-1271 suppresses the proliferation and invasion of prostate cancer cells. Biochem Biophys Res Commun 484(4):794–800CrossRefPubMed Zhong J et al (2017) Inhibition of DIXDC1 by microRNA-1271 suppresses the proliferation and invasion of prostate cancer cells. Biochem Biophys Res Commun 484(4):794–800CrossRefPubMed
28.
Zurück zum Zitat Yang M et al (2014) miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2. Anti Cancer Agents Med Chem 14(6):884–891CrossRef Yang M et al (2014) miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2. Anti Cancer Agents Med Chem 14(6):884–891CrossRef
Metadaten
Titel
MiR-1271 Inhibits Cell Growth in Prostate Cancer by Targeting ERG
verfasst von
Miao Wang
Wei Gao
Dehong Lu
Lianghong Teng
Publikationsdatum
27.05.2017
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 2/2018
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-017-0254-y

Weitere Artikel der Ausgabe 2/2018

Pathology & Oncology Research 2/2018 Zur Ausgabe

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.